Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia Publisher Pubmed



Solaymanidodaran M1, 2, 3 ; Ghanei M4 ; Bagheri M5 ; Qazvini A6 ; Vahedi E7 ; Hassan Saadat S8 ; Amin Setarehdan S1, 3 ; Ansarifar A3 ; Biganeh H9 ; Mohazzab A3, 10 ; Khalili D11 ; Hosein Ghazale A9 ; Reza Heidari M9 ; Taheri A9 Show All Authors
Authors
  1. Solaymanidodaran M1, 2, 3
  2. Ghanei M4
  3. Bagheri M5
  4. Qazvini A6
  5. Vahedi E7
  6. Hassan Saadat S8
  7. Amin Setarehdan S1, 3
  8. Ansarifar A3
  9. Biganeh H9
  10. Mohazzab A3, 10
  11. Khalili D11
  12. Hosein Ghazale A9
  13. Reza Heidari M9
  14. Taheri A9
  15. Khoramdad M3
  16. Mahdi Asadi M9
  17. Nazemieh M12
  18. Varshochi M13
  19. Abbasian S14
  20. Bakhtiari A15
  21. Mosaed R16
  22. Hosseinishokouh SJ17
  23. Shahrokhi M18
  24. Yassin Z19
  25. Ali Zohal M20
  26. Qaraati M20
  27. Rastgoo N20
  28. Sami R21
  29. Javad Eslami M22
  30. Asghari A23
  31. Namazi M24
  32. Ziaie S25
  33. Jafarimoghaddam R25
  34. Kalantari S19
  35. Memarian M26
  36. Khodadadi J27
  37. Hossein Afshari M28
  38. Momenheravi M29
  39. Behzadseresht N30
  40. Reza Mobayen A31
  41. Mozafari A32
  42. Movasaghi F32
  43. Haddadzadeh Shoushtari M33
  44. Moazen J15

Source: International Immunopharmacology Published:2021


Abstract

Background: We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2. Methods: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO2) of less than 93% were enrolled. They were randomly allocated into Favipiravir (1.6 gr loading, 1.8 gr daily) and Lopinavir/Ritonavir (800/200 mg daily) treatment regimens in addition to standard care. In-hospital mortality, ICU admission, intubation, time to clinical recovery, changes in daily SpO2 after 5 min discontinuation of supplemental oxygen, and length of hospital stay were quantified and compared in the two groups. Results: 380 patients were randomly allocated into Favipiravir (1 9 3) and Lopinavir/Ritonavir (1 8 7) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days [SD = 6] in the Favipiravir and 8.1 [SD = 6.5] days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 – 1.17) and likewise the changes in the daily SpO2 after discontinuation of supplemental oxygen (p = 0.46) Conclusion: Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery and length of hospital stay. © 2021 Elsevier B.V.
Other Related Docs
7. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
17. Potential Treatments for Covid-19; a Narrative Literature Review, Archives of Academic Emergency Medicine (2020)